查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1360316

细胞和基因治疗製造品质控制 (QC) 市场（组成部分：设备和配件、消耗品等）- 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 202 Pages | 商品交期: 2-10个工作天内

价格

细胞和基因治疗製造品质控制 (QC) 市场 - 报告范围

TMR 关于全球细胞和基因治疗製造品质控制 (QC) 市场的报告研究了过去和当前的成长趋势以及机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供2017-2031年期间全球细胞和基因治疗製造品质控制（QC）市场的收入，以2023年为基准年，2031年为预测年。该报告还提供了2023年至2031年全球细胞和基因治疗製造品质控制（QC）市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解细胞和基因治疗製造品质控制 (QC) 市场。

市场概况
2023年市场价值 3.717 亿美元
2031 年市场价值 28亿美元
复合年增长率 24.6%

该报告深入研究了全球细胞和基因治疗製造品质控制（QC）市场的竞争格局。全球细胞和基因治疗製造品质控制 (QC) 市场的主要参与者已被确定，并且每个参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球细胞和基因治疗製造品质控制 (QC) 市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球细胞和基因治疗製造品质控制 (QC) 市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 技术进步
  • 重要行业活动
  • 按地区/全球分類的监管情景
  • 主要研究机构参与
  • COVID-19 大流行对该行业的影响

第 6 章：全球分析与预测：按组成部分

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按组成部分，2017-2031
    • 设备及配件
    • 耗材
    • 其他的
  • 市场吸引力分析：按组成部分

第 7 章：全球分析与预测：透过分析方法

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：2017-2031年分析法
    • 无菌检测
    • 纯度检测
    • 效力测试
    • 身份测试
    • 其他的
  • 市场吸引力分析：分析法

第 8 章：全球市场分析与预测：按流程

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依流程，2017-2031
    • 上游流程
    • 下游流程
    • 製程开发
  • 市场吸引力分析：按流程

第 9 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2017-2031
    • 製药与生物技术公司
    • 合约製造组织 (CMO)
  • 市场吸引力分析：按最终用户

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分，2022 年
  • 公司简介
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • QIAGEN
    • Charles River Laboratories International, Inc.
    • Lonza Group AG
    • Merck KGaA
    • Intertek Group plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
Product Code: TMRGL85805

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing quality control (QC) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing quality control (QC) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing quality control (QC) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing quality control (QC) market.

Market Snapshot
Market Value in 2023US$ 371.7 Mn
Market Value in 2031US$ 2.8 Bn
CAGR24.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing quality control (QC) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing quality control (QC) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing quality control (QC) market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing quality control (QC) market. Key players operating in the global cell and gene therapy manufacturing quality control (QC) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing quality control (QC) market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Report:

  • What is the sales/revenue generated by cell and gene therapy manufacturing quality control (QC) across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing quality control (QC) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing quality control (QC) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing quality control (QC) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing quality control (QC) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. Major Research Institutes Involved
  • 5.5. COVID-19 Pandemic Impact on Industry

6. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Component

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Component, 2017-2031
    • 6.3.1. Equipment & Accessories
    • 6.3.2. Consumables
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Component

7. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Analytical Method

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 7.3.1. Sterility Testing
    • 7.3.2. Purity Testing
    • 7.3.3. Potency Testing
    • 7.3.4. Identity Testing
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Analytical Method

8. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Process

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Process, 2017-2031
    • 8.3.1. Upstream Processes
    • 8.3.2. Downstream Processes
    • 8.3.3. Process Development
  • 8.4. Market Attractiveness Analysis, by Process

9. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Pharmaceutical & Biotechnology Companies
    • 9.3.2. Contract Manufacturing Organizations (CMOs)
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Component, 2017-2031
    • 11.2.1. Equipment & Accessories
    • 11.2.2. Consumables
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 11.3.1. Sterility Testing
    • 11.3.2. Purity Testing
    • 11.3.3. Potency Testing
    • 11.3.4. Identity Testing
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Process, 2017-2031
    • 11.4.1. Upstream Processes
    • 11.4.2. Downstream Processes
    • 11.4.3. Process Development
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Pharmaceutical & Biotechnology Companies
    • 11.5.2. Contract Manufacturing Organizations (CMOs)
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Component
    • 11.7.2. By Analytical Method
    • 11.7.3. By Process
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Component, 2017-2031
    • 12.2.1. Equipment & Accessories
    • 12.2.2. Consumables
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 12.3.1. Sterility Testing
    • 12.3.2. Purity Testing
    • 12.3.3. Potency Testing
    • 12.3.4. Identity Testing
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Process, 2017-2031
    • 12.4.1. Upstream Processes
    • 12.4.2. Downstream Processes
    • 12.4.3. Process Development
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Pharmaceutical & Biotechnology Companies
    • 12.5.2. Contract Manufacturing Organizations (CMOs)
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Component
    • 12.7.2. By Analytical Method
    • 12.7.3. By Process
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Component, 2017-2031
    • 13.2.1. Equipment & Accessories
    • 13.2.2. Consumables
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 13.3.1. Sterility Testing
    • 13.3.2. Purity Testing
    • 13.3.3. Potency Testing
    • 13.3.4. Identity Testing
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Process, 2017-2031
    • 13.4.1. Upstream Processes
    • 13.4.2. Downstream Processes
    • 13.4.3. Process Development
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Pharmaceutical & Biotechnology Companies
    • 13.5.2. Contract Manufacturing Organizations (CMOs)
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Component
    • 13.7.2. By Analytical Method
    • 13.7.3. By Process
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Component, 2017-2031
    • 14.2.1. Equipment & Accessories
    • 14.2.2. Consumables
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 14.3.1. Sterility Testing
    • 14.3.2. Purity Testing
    • 14.3.3. Potency Testing
    • 14.3.4. Identity Testing
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Process, 2017-2031
    • 14.4.1. Upstream Processes
    • 14.4.2. Downstream Processes
    • 14.4.3. Process Development
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Pharmaceutical & Biotechnology Companies
    • 14.5.2. Contract Manufacturing Organizations (CMOs)
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Component
    • 14.7.2. By Analytical Method
    • 14.7.3. By Process
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Component, 2017-2031
    • 15.2.1. Equipment & Accessories
    • 15.2.2. Consumables
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 15.3.1. Sterility Testing
    • 15.3.2. Purity Testing
    • 15.3.3. Potency Testing
    • 15.3.4. Identity Testing
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Process , 2017-2031
    • 15.4.1. Upstream Processes
    • 15.4.2. Downstream Processes
    • 15.4.3. Process Development
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Pharmaceutical & Biotechnology Companies
    • 15.5.2. Contract Manufacturing Organizations (CMOs)
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Component
    • 15.7.2. By Analytical Method
    • 15.7.3. By Process
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. bioMerieux SA
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Bio-Rad Laboratories, Inc.
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Bio-Techne Corporation
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. QIAGEN
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Charles River Laboratories International, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Lonza Group AG
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Merck KGaA
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Intertek Group plc
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Thermo Fisher Scientific Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Eurofins Scientific S.E.
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. F. Hoffmann-La Roche Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments

List of Tables

  • Table 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 02: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 03: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 04: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 07: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 08: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 09: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 10: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 12: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 13: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 14: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 17: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 18: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 19: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 20: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 23: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 24: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 25: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 28: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 29: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 30: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Cell and Gene Therapy Manufacturing QC Market Value Share, by Component, 2022
  • Figure 03: Cell and Gene Therapy Manufacturing QC Market Value Share, by Product Type, 2022
  • Figure 04: Cell and Gene Therapy Manufacturing QC Market Value Share, by Process, 2022
  • Figure 05: Cell and Gene Therapy Manufacturing QC Market Value Share, by End-user, 2022
  • Figure 06: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 07: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component, 2023-2031
  • Figure 08: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Equipment & Accessories, 2017-2031
  • Figure 09: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Consumables, 2017-2031
  • Figure 10: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Others, 2017-2031
  • Figure 11: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 12: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 13: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Sterility Testing, 2017-2031
  • Figure 14: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Urological Surgery, 2017-2031
  • Figure 15: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Potency Testing, 2017-2031
  • Figure 16: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Identity Testing, 2017-2031
  • Figure 17: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 18: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 19: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Process, 2023-2031
  • Figure 20: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Upstream Processes, 2017-2031
  • Figure 21: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Downstream Processes, 2017-2031
  • Figure 22: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Process Development, 2017-2031
  • Figure 23: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 24: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 25: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 26: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Contract Manufacturing Organizations (CMOs), 2017-31
  • Figure 27: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 28: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 29: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 31: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 32: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 33: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 34: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 35: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 36: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 37: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 38: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 39: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 40: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 44: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 45: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 46: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 47: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 48: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 49: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 50: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 51: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 55: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 56: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 57: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 58: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 59: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 60: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 61: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 62: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 63: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 65: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 66: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 67: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 68: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 69: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 70: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 71: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 72: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 73: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 74: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 75: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 76: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 77: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 78: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 79: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 80: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 81: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 82: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 83: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031